TrialJournal of the European Academy of Dermatology and Venereology : JEADV2026

Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.

Melinda J Gooderham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.